Company Filing History:
Years Active: 2006-2014
Title: David Igo: Innovator in Pharmaceutical Chemistry
Introduction
David Igo is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for cancer treatment. With a total of 3 patents, his work has had a meaningful impact on medical research and drug development.
Latest Patents
One of David Igo's latest patents involves the invention of crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. This invention relates to three distinct crystalline forms, designated as Form A, Form B, and Form C. The invention provides methods for the treatment of cancer by modulating protein kinase activity. Additionally, it includes pharmaceutical compositions containing a crystalline form of the compound along with a pharmaceutically acceptable excipient. Another significant patent includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-β-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.
Career Highlights
Throughout his career, David Igo has worked with prominent companies in the pharmaceutical industry. He has been associated with SmithKline Beecham Corporation and Exelixis, Inc., where he contributed to various innovative projects. His expertise in pharmaceutical chemistry has been instrumental in advancing drug development processes.
Collaborations
David Igo has collaborated with notable colleagues such as Paul R Johnson and Daniel Patterson. These collaborations have fostered a productive environment for innovation and research in the pharmaceutical field.
Conclusion
David Igo's contributions to pharmaceutical chemistry and his innovative patents demonstrate his commitment to advancing medical science. His work continues to influence the development of effective treatments for cancer and other diseases.